(June14) ENDO 2026 Satellite Symposia: The Amylin Arcade: Level Up Your Knowledge of Amylin-Based Therapies for Obesity Management: Advancements in obesity research have revolutionized our understanding of the disease as a complex disorder of energy dysregulation. These insights have paved the way for novel therapeutic approaches. Among these, amylin—a key hormone involved in satiety, gastric emptying, and regulation of energy balance—has emerged as a promising new pharmacologic target. As amylin-based agents progress through clinical development, clinician awareness of amylin’s physiologic role and therapeutic potential has become increasingly essential.

(Summer 2026) Urge Your Member of Congress to Cosponsor the Treat and Reduce Obesity Act (TROA): This legislation would allow coverage of anti-obesity medications (AOMs) currently prohibited in the Medicare statute and expand access to intensive behavioral therapy (IBT) for obesity. It is critical that your Senators and Representatives hear from you on the importance of cosponsoring this legislation. Endocrine Society members are encouraged to take action to share the importance of cosponsoring this legislation.

(April 2026) Editors of The Journal of Clinical Endocrinology & Metabolism, Endocrinology, Journal of the Endocrine Society, JCEM Case Reports, and Endocrine Reviews have selected recently published articles that advance understanding of obesity and the roles of diet and exercise in metabolic health. Articles were curated based on citations, downloads, and editorial recognition.